---
title: "Pfizer: 3 key takeaways for long-term investors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304304114.md"
description: "The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue."
datetime: "2026-11-04T15:00:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304304114.md)
  - [en](https://longbridge.com/en/news/304304114.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304304114.md)
generator: "portal-rs"
---

# Pfizer: 3 key takeaways for long-term investors

The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue.

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md)
- [Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes](https://longbridge.com/en/news/305535476.md)
- [Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028](https://longbridge.com/en/news/304872583.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**